ResMed Forecast, price target & analysts
ResMed Target price 2026 - Analyst rating & recommendation
ResMed Classifications & Recommendation
ResMed Price Target
| Target Price | $239.70 |
| Price | $221.15 |
| Potential |
8.39%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target ResMed 2027 .
The average ResMed target price is $239.70.
This is
8.39%
register free of charge
$336.00
51.93%
register free of charge
$176.75
20.08%
register free of charge
|
|
| A rating was issued by 27 analysts: 13 Analysts recommend ResMed to buy, 12 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ResMed stock has an average upside potential 2027 of
8.39%
register free of charge
|
Sales and Margin forecast 2027, 2028 & 2029
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion $ | 5.65 | 5.87 |
| 9.85% | 3.83% | |
| EBITDA Margin | 34.76% | 38.81% |
| 3.35% | 11.64% | |
| Net Margin | 26.94% | 60.27% |
| 1.00% | 123.68% |
29 Analysts have issued a sales forecast ResMed 2027 . The average ResMed sales estimate is
This results in the following potential growth metrics:
23 Analysts have issued an ResMed EBITDA forecast 2027. The average ResMed EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 ResMed Analysts have issued a net profit forecast 2027. The average ResMed net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 10.43 | 12.20 |
| 9.67% | 16.97% | |
| P/E | 18.13 | |
| EV/Sales | 5.30 |
23 Analysts have issued a ResMed forecast for earnings per share. The average ResMed EPS is
This results in the following potential growth metrics and future valuations:
Current ResMed Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 15 2026 |
| Keybanc |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| Rothschild & Co |
Locked
➜
Locked
|
Locked | Aug 19 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Keybanc |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 15 2026 |
|
Locked
Keybanc:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
Rothschild & Co:
Locked
➜
Locked
|
Aug 19 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Keybanc:
Locked
➜
Locked
|
Aug 07 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
